This up-and-coming cancer treatment could be a $25 billion market opportunity — it's already a hotbed for M&A

Skynesher | E+ | Getty Images

Big pharma is betting billions on an up-and-coming class of cancer treatments that some on Wall Street are calling a "massive opportunity."

It's called targeted radiopharmaceuticals. The therapy essentially delivers radiation directly into tumors by attaching a radioactive particle to a targeting molecule.

RBC Capital Markets sees a $25 billion market opportunity for the space.

"We believe TRT development is still in its early stages, and next-generation technologies that enable improvements in therapeutic potency and address a wider range of cancer targets have the potential to drive value creation in the space," analyst Gregory Renza, M.D., wrote in a February note.

Four acquisitions in the space were announced in just the last several months. The latest was by Novartis, which already has two targeted radiotherapies on the market. Pluvicto treats a certain type of advanced prostate cancer, while Lutathera targets neuroendocrine tumors.

Pluvicto, which faced some now-resolved supply constraints last year, is nearing blockbuster status, bringing in $980 million in sales in 2023. By 2028, the two drugs combined are expected to generate $5 billion in revenue, Renza said.

Stock Chart IconStock chart icon

Novartis' one-year performance

A market leader with 'an aggressive strategy'

Earlier this month, Novartis said it entered into an agreement to acquire Mariana Oncology for $1 billion. The preclinical-stage company is focused on developing radiopharmacutical programs, also known as radioligand therapies, that treat breast, prostate and lung cancers. One candidate, known as MC-339, is being researched for small cell lung cancer.

"They're clearly the market leader in this space with an aggressive strategy, both successfully commercializing their products, expanding the market opportunities for those products, and having a pipeline behind that," said Oppenheimer analyst Jeff Jones. "Acquiring Mariana ... gives them even greater discovery capabilities."

Shares are up about 1% year to date. The average analyst rating is hold, with 8% upside to the average analyst price target, according to FactSet.

Read CNBC Pro to learn how to invest this trend:

A corner of the cancer therapy market is heating up—Here are the names investors need to know

Novartis' success has lit a fire under its competitors. Piper Sandler analyst Edward Tenthoff characterizes it as "FOMO," or the fear of missing out.

"I think that's what's happening and big pharma is accumulating capabilities in this new modality," he said.

Eli Lilly, which has benefited from the excitement in the GLP-1 space with its diabetes drug Mounjaro and weight-loss treatment Zepbound, completed its $1.4 billion acquisition of radiopharmaceutical company Point Biopharma in December.

Just before the deal closed, Point Biopharma's targeted radiation drug, known as PNT2002, met its primary endpoint in a phase three trial for metastatic castration-resistant prostate cancer.

In addition, earlier this week Eli Lilly announced it will pay Aktis Oncology $60 million to use its novel miniprotein technology platform to generate anticancer radiopharmaceuticals.

Eli Lilly has an average analyst rating of overweight and 8.3% upside to the average analyst price target, per FactSet. Shares have already run up nearly 38% so far this year.

"Obviously, investors are very focused on obesity right now, I believe, but we think with their acquisition, they have opportunities certainly on the supply side, which is one of the challenges facing radiopharma companies," said investor Dan Lyons, a portfolio manager and research analyst at Janus Henderson Investors.

Bristol-Myers Squibb has also joined the fray, completing its $4.1 billion acquisition of RayzeBio in February. The company now has RazyeBio's pipeline, including its late-stage targeted radiopharma therapy, RYZ101, for gastroenteropancreatic neuroendocrine tumors. It is also in a phase one trial for small cell lung cancer.

The deal's announcement in December came shortly after Bristol-Myers Squibb said it would spend $14 billion to buyout schizophrenia drug developer Karuna Therapeutics. At the time, William Blair analyst Matt Phipps said the deals show Bristol's urgency to bring in more products since some of its older therapies are set to lose their patent protections later this decade.

Shares of the big pharma company have been on a losing streak, down more than 18% year to date. It has an average analyst rating of hold, per FactSet.

Lastly, in March, AstraZeneca announced plans to purchase clinical-stage biopharmaceutical company Fusion Pharmaceuticals for $2.4 billion. Fusion currently has a phase two clinical trial underway for a potential new treatment, called FPI-2265, for patients with metastatic castration-resistant prostate cancer.

Stock Chart IconStock chart icon

AstraZeneca's one-year performance

AstraZeneca shares have an average analyst rating of overweight and nearly 6% upside to the average analyst price target, per FactSet.

"All these companies had manufacturing presence, more or less, built out or are in the process of building out and becoming operational very soon on a commercial scale," said Jefferies analyst Andrew Tsai. "They've got that locked down and I think that's, in part, what big pharma wanted."

There are also some smaller publicly-traded biopharma companies still standing, although not many.

In addition, there are several private companies in the space that have have been attracting private investors, especially of late. Innovative radiopharmaceutical drugs nabbed in $518 million in venture financing last year, a whopping 722% increase from the $63 million they received in 2017, according to GlobalData's Pharma Intelligence Center Deals Database.

Both those public and private names could be ripe for an acquisition at some point, said Janus Henderson's Lyons.

"There are several large pharma companies that don't yet have radiopharma programs that may be interested in this space," he said. "In addition, I think some of the players that already have programs will be interested in finding additional targets and pipeline programs to augment their portfolio."

'Massive opportunity'

Everyone, including big pharma, is working on either improving on existing treatments or looking to expand into attacking different cancer tumors.

Novartis, for instance, got FDA approval in April for Lutathera for pediatric patients. It also said last month that it will file for a label expansion for Pluvicto in earlier treatment of prostate cancer.

"There's a clear path and strategy by Novartis to expand the market opportunity for those two products," Jones said.

Then there are companies that are developing therapies against those same targets. Some, like Bristol's RayzeBio, are turning to using an alpha emitter like actinium instead of the beta emitter lutetium used by Pluvicto and Lutathera.

"These alpha [emitters] have a much stronger punch and are very localized, literally, to a cell length," said Piper Sandler's Tenthoff.

Stock Chart IconStock chart icon

Bristol-Myers Squibb's one-year performance

Radiopharmaceuticals are also being looked at to use in conjunction with other treatments, such as immunotherapy.

Depending on the outcome of current and future clinical trials, the therapy could also eventually be used to treat any cancers like ovarian, breast or brain, he said.

"Anywhere where radiation therapy is used, but not necessarily in a targeted approach, makes a lot of sense because these are radiosensitive tumors," Tenthoff said.

Companies can also turn the decades of research they've already done in the field to identify new opportunities, Jones said.

"You can really leverage all the work we've done in cancer over the last 30 to 40 years to identify targets on cancer cells that are not expressed, or much more highly expressed on cancer cells versus normal cells —and really, any of those are an opportunity for targeted radiotherapy," he said.

"I see the massive opportunity for targeted radiotherapies," he added. "We have two products today, two targets and you have essentially the entire universe of cancer research and cancer targeting."

Don’t miss these exclusives from CNBC PRO

  • Wednesday's analyst calls: Analysts discussed Alphabet and a Chinese electric vehicle maker.
  • CPI report: Inflation eased in April, with consumer prices still rising 3.4% from a year ago.
  • Trading CPI: How stocks could react to Wednesday's inflation report
  • Berkshire Hathaway reported Q1 2024 figures, revealing that most of the conglomerate's stock portfolio is focused on just five stocks.
  • CNBC Pro scoured Goldman Sach's May conviction lists for stocks with further upside of 50% or more, based on the bank's price targets.

OTHER NEWS

20 minutes ago

William grins at King's Pokemon joke

20 minutes ago

US election body gives Trump another 45 days for personal financial disclosures

20 minutes ago

Forza Horizon 4 is being removed from sale because of expiring licenses, but at least it'll keep running after it's gone

23 minutes ago

Pharmacy Guild ‘blindsided’ by Labor-Greens deal on vapes

23 minutes ago

Why electric vehicle prices are falling

23 minutes ago

Seven Potential Klay Thompson Destinations in NBA Free Agency

24 minutes ago

Nine Australians locked in to compete in tennis at the Paris Olympics

25 minutes ago

WikiLeaks' founder Assange pleads guilty in deal with US that secures his freedom, ends legal fight

26 minutes ago

Video: Love Island villa is shaken by the arrival of TWO new bombshells as they each pick one person to date

26 minutes ago

Video: Love Island villa is shaken by the arrival of TWO new bombshells as they each pick one person to date

28 minutes ago

David Warner posts a beery photo after his last game for Australia - but it's NOTHING like what you'd expect - as wife Candice has a very surprising reaction

29 minutes ago

Kingdom Hearts, As Told By Steam Reviews

29 minutes ago

England vs Slovenia player ratings: Jude Bellingham and Conor Gallagher disappoint at Euro 2024

29 minutes ago

Superstar Calvin Harris is Coming to Bahrain on This Date!

30 minutes ago

Austria beat Netherlands in five-goal Euro 2024 thriller to top Group D

30 minutes ago

Rocky Mountain tourist learns the hard way not to get between a mother bear and her cubs

30 minutes ago

Creative Overwatch 2 Fan Comes Up With Baldur's Gate 3 Skin Concepts

30 minutes ago

Life By You is Canceled, But Another Sims Competitor is Still Coming

30 minutes ago

Afghanistan in T20 World Cup semifinal: A real fairy tale?

30 minutes ago

Eagles' Brandon Graham happy Saquon Barkley joined team, says losing star RB 'sucked for the Giants fans'

30 minutes ago

Watch: San Diego Zoo celebrates birth of endangered Baird's tapir

30 minutes ago

Why the Netherlands wear orange whilst playing football

30 minutes ago

Elden Ring Fan Creates Incredible Acrylic Painting of The Lands Between

30 minutes ago

England 0-0 Slovenia: player ratings from the Euro 2024 Group C game

30 minutes ago

Cups thrown at England manager Gareth Southgate after 0-0 draw with Slovenia

31 minutes ago

Airplane suddenly drops 25,000 feet midflight, injuring 17 passengers

32 minutes ago

Asia-Pacific markets mostly lower ahead of Australia's May inflation figures

32 minutes ago

After losing home, family hopes for historic café’s survival as Rapidan Dam collapse looms

34 minutes ago

Attractions work on affordability to draw staycationing Calgarians this summer

36 minutes ago

Video: Lemurs in the wild serenade each other with a distinct rhythm, study finds - suggesting the ability to sing evolved early in primates

36 minutes ago

Joe and Jill Biden refinanced their Delaware home 20 times — raking in $4.2M from the $350K property

37 minutes ago

Boxing-Usyk vacates IBF heavyweight title

37 minutes ago

FTX customers to vote on multi-billion dollar repayment plan

37 minutes ago

New footage of Adelaide Westfield shopping centre incident emerges

37 minutes ago

Lytton, B.C., rebuild continues three years after wildfire destroyed most of town

37 minutes ago

Report: Dallas Cowboys’ Stephen Jones Is ‘Pulling’ Jerry Jones Back From Going All-In On Free Agency

37 minutes ago

‘We’re confident’: Not over yet for Cats great

37 minutes ago

Anti-Labour placards backfire for the Green Party

37 minutes ago

Millionaire residents fury that town has turned into dumping ground

37 minutes ago

Bears D-line gets poor ranking ahead of 2024 season